PYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64mood

MRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10mood

RBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47mood

GLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31mood

GE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04mood

MELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88mood

ETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35mood

PD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08mood

COST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44mood

StockSays

GRI

← Markets

GRIGRI Bio, Inc.

Discussion

Nothing said here yet.

to join the conversation.

—

Thu, Aug 27
8:01 AMglobenewswire.comGRI Bio Featured in "Why Now" On-Demand Video Webcast
Mon, Aug 24
8:05 AMglobenewswire.comGRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
Thu, Jun 18
7:31 AMYahooGRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
Mon, May 18
8:15 AMYahooGRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
Thu, May 14
7:35 AMYahooGRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRI · GRI Bio, Inc. — sentiment, insiders, filings